KYTX (STOCKS)
Kyverna Therapeutics, Inc. Common Stock
$8.080000
+0.030000 (+0.37%)
Prev close: $8.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Warner Biddle
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $535.96M
- Employees
- 129
- P/E (TTM)
- -2.74
- P/B (TTM)
- 2.99
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $6.29M |
| Operating Expenses | $158.93M |
| Research and Development | $115.33M |
| Other Operating Expenses | $43.60M |
| Operating Income/Loss | -$158.93M |
| Income/Loss From Continuing Operations After Tax | -$152.64M |
| Income/Loss From Continuing Operations Before Tax | -$152.64M |
| Net Income/Loss | -$152.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$152.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$152.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.93 |
| Diluted Earnings Per Share | -$2.93 |
| Basic Average Shares | 105,058,069 |
| Diluted Average Shares | 105,058,069 |
| Assets | $219.82M |
| Current Assets | $206.54M |
| Cash | $199.40M |
| Other Current Assets | $7.14M |
| Noncurrent Assets | $13.28M |
| Fixed Assets | $1.33M |
| Other Non-current Assets | $11.96M |
| Liabilities | $54.27M |
| Current Liabilities | $22.80M |
| Accounts Payable | $2.93M |
| Other Current Liabilities | $19.87M |
| Noncurrent Liabilities | $31.47M |
| Equity | $165.55M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $165.55M |
| Liabilities And Equity | $219.82M |
| Net Cash Flow From Operating Activities | -$158.75M |
| Net Cash Flow From Operating Activities, Continuing | -$158.75M |
| Net Cash Flow From Investing Activities | -$8.80M |
| Net Cash Flow From Investing Activities, Continuing | -$8.80M |
| Net Cash Flow From Financing Activities | $145.92M |
| Net Cash Flow From Financing Activities, Continuing | $145.92M |
| Net Cash Flow | -$21.63M |
| Net Cash Flow, Continuing | -$21.63M |
| Comprehensive Income/Loss | -$152.57M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$152.76M |
| Other Comprehensive Income/Loss | -$112.84M |
| Other Comprehensive Income/Loss Attributable To Parent | -$122.00K |